Department of Ophthalmology, Laboratory of Experimental Ophthalmology, PIUS-HOSPITAL, Carl-von-Ossietzky University, Oldenburg, Germany.
Curr Eye Res. 2020 Mar;45(3):230-240. doi: 10.1080/02713683.2019.1637438. Epub 2019 Jul 9.
Dry eye disease (DED) is a complex and multifactorial disease resulting in a continual cycle of tear hyperosmolarity and inflammation. Patients suffering from DED experience severe pain and visual impairments leading to a reduced quality of life. Aqueous-deficient dry eye (ADDE), mainly caused through a loss of functional lacrimal gland tissue, results in the most severe forms of DED. Despite a high prevalence, the current treatments remain palliative and may be insufficient to alleviate the symptoms. Consequently, investigations on experimental approaches for lacrimal gland regeneration are of great clinical interest. This article reviews the current knowledge about processes involved in lacrimal gland regeneration, about lacrimal gland resident stem cells, and offers deductions about possible concepts for lacrimal gland regeneration. Promising starting points might be the utilization of therapeutic proteins, such as bone morphogenetic protein 7, mesenchymal stem cells (MSC) or MSC-based treatments such as conditioned medium, lyophilized cell extracts or adult acinar cells. This review further summarizes current experimental approaches for the treatment of ADDE in animal models and patients. Approaches investigating side population stem cells, epithelial progenitor cells and MSC showed that the transplantation of these cells had therapeutic effects on ADDE. However, the most promising and best-studied experimental approach is the use of MSC for induction/enhancement of lacrimal gland regeneration. Their immunomodulatory effects, low immunogenicity, promotion of tissue regeneration and involvement during spontaneous lacrimal regeneration are favorable traits for clinical applications. In addition, the efficacy and safety of allogeneic MSC transplantation have already been demonstrated in a small patient cohort.
干眼症(DED)是一种复杂的多因素疾病,导致持续的泪液高渗和炎症循环。患有 DED 的患者会经历严重的疼痛和视力障碍,导致生活质量下降。水液缺乏性干眼症(ADDE)主要是由于功能性泪腺组织丧失引起的,导致最严重的 DED 形式。尽管患病率很高,但目前的治疗方法仍然是姑息性的,可能不足以缓解症状。因此,对泪腺再生的实验方法的研究具有重要的临床意义。本文综述了目前关于泪腺再生过程、泪腺固有干细胞的知识,并对可能的泪腺再生概念进行了推断。有前途的起点可能是利用治疗性蛋白,如骨形态发生蛋白 7、间充质干细胞(MSC)或基于 MSC 的治疗,如条件培养基、冻干细胞提取物或成年腺泡细胞。本综述进一步总结了目前在动物模型和患者中治疗 ADDE 的实验方法。研究侧群干细胞、上皮祖细胞和 MSC 的方法表明,这些细胞的移植对 ADDE 具有治疗作用。然而,最有前途和研究最多的实验方法是使用 MSC 诱导/增强泪腺再生。它们的免疫调节作用、低免疫原性、促进组织再生以及在自发泪腺再生过程中的参与是临床应用的有利特征。此外,同种异体 MSC 移植的疗效和安全性已经在一小部分患者中得到了证实。